OPKO HEALTH, INC. (OPK) Stock
1 member of Congress disclosed 3 trades in OPK since 2017: 3 purchases and 0 sales, most recently Carlos Curbelo (purchase, Sep 26, 2017). 3 of the hedge funds AlphaScala tracks reported OPK in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $2.13M.
Which members of Congress traded OPKO HEALTH, INC. (OPK)?
Most recent: Carlos Curbelo (purchase, Sep 26, 2017); records start Feb 7, 2017.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Carlos Curbelo R-FL · House | 2017-09-26 | purchase | $1k – $15k |
| Carlos Curbelo R-FL · House | 2017-03-02 | purchase | $1k – $15k |
| Carlos Curbelo R-FL · House | 2017-02-07 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 20, 2026.
See all OPK political trades →Which hedge funds own OPK?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 1.42M | $2.13M | -32% |
| Point72 Steve Cohen | 145K | $217.9K | +56% |
| Millennium Management Israel Englander | 72K | $108.5K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →OPK price chart
Powered by TradingViewWhat does OPKO HEALTH, INC. do?
OpKO Health Inc. is a multinational biopharmaceutical and diagnostics company operating through two primary segments: Pharmaceuticals and Diagnostics. In the Pharmaceuticals segment, it develops and commercializes therapies such as Rayaldee, FDA-approved for treating secondary hyperparathyroidism in adults with chronic kidney disease and vitamin D insufficiency, and Somatrogon (hGH-CTP), approved in over 50 markets for growth hormone deficiency in children and adolescents. The company advances multispecific therapies targeting cancers and infectious diseases, partnering with leading pharmaceutical firms to deliver next-generation solutions for serious conditions across global markets. Its Diagnostics segment, primarily through BioReference Health, LLC, provides comprehensive clinical laboratory testing services, including the 4Kscore prostate cancer test, serving physicians, hospitals, clinics, and healthcare facilities nationwide with a network of labs. Founded in 1991 and headquartered in Miami, Florida, OpKO Health Inc. focuses on improving patient outcomes in healthcare and biopharmaceutical sectors.